USRE40045E1 - Medicaments - Google Patents

Medicaments Download PDF

Info

Publication number
USRE40045E1
USRE40045E1 US10/933,483 US93348304A USRE40045E US RE40045 E1 USRE40045 E1 US RE40045E1 US 93348304 A US93348304 A US 93348304A US RE40045 E USRE40045 E US RE40045E
Authority
US
United States
Prior art keywords
salmeterol
fluticasone propionate
composition
physiologically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/933,483
Inventor
James B. D. Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to US10/933,483 priority Critical patent/USRE40045E1/en
Application granted granted Critical
Publication of USRE40045E1 publication Critical patent/USRE40045E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Abstract

Pharmaceutical compositions comprising effective amounts of salmeterol (and a physiologically acceptable salt thereof) and fluctuations propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.

Description

This application is a continuation of U.S. patent application Ser. No. 07/578,601, filed Sept. 7, 1990.
This application is a continuation of U.S. patent application Ser. No. 07/578,601, filed Sep. 7, 1990, now abandoned.
This invention relates to improvements in the treatment of asthma and other respiratory disorders. More particularly, it relates to the use of a bronchodilator drug in combination with a steroidal anti-inflammatory drug for the treatment of respiratory disorders such as asthma, and to pharmaceutically compositions containing the two active ingredients.
Asthma is a condition characterized by variable, reversible obstruction of the airways which is caused by a complex inflammatory process within the lungs. In most cases, this process is initiated and maintained by the inhalation of antigens by sensitive atopic individuals (extrinsic asthma). However, in some patients it is caused by other mechanisms which at present are poorly understood but do not involve an allergic process (intrinsic asthma). The disease has therefore two components, spasm of the bronchial (or breathing) tubes and inflammation or swelling of the breathing tubes.
Salbutamon, the first highly selective β2-adrenoceptor stimulant has been used successfully and effectively by inhalation for the immediate relief of spasm in asthma. However, when given by inhalation, salbutamol has usually a four to six hour duration of action, which is too short either to control nocturnal asthma or for convenient maintenance of the disease in some patients.
Anti-inflammatory corticosteroids such as, for example, beclomethasone dipropionate have also been administered by inhalation in the treatment of asthma, although unlike salbutamol the therapeutic benefits resulting from reduced inflammation may not be immediately apparent.
It has been recognized that asthma may be treated by using both a bronchodilator or immediate relief and a prophylactic anti-inflammatory corticosteroid to treat the underlying inflammation. Such combination therapy directed at the two main underlying events in the lung (i.e., relief of spasm in the breathing tubes and treatment of inflammation in the breathing tubes) using a combination of salbutamol and beclomethasone dipropionate has previously been proposed (Ventide, Glaxo Group trade mark), but suffers a number of disadvantages in view of the above-mentioned short duration of action exhibited by salbutamol. Thus the need for a 4-hourly dosing regimen may discourage effective patient compliance and also renders the product less than satisfactory in the treatment of nocturnal asthma since the bronchodilator may no remain effective for the duration of the night, leading to impaired sleep for asthmatics troubled by nocturnal cough, breathlessness and wheeze.
The present invention is based on the concept of a novel combination therapy which has markedly greater efficiency and duration of bronchodilator action than previously known combinations and which permits the establishment of a twice daily (bis in dime—b.i.d.) dosing regimen with consequent substantial benefits in, for example, the treatment of asthma, particularly nocturnal asthma.
Thus we have found we believe that if the β2-adrenoreceptor stimulant brochodilator salmeterol and/or a physiologically acceptable salt thereof is combined with the anti-inflammatory corticosteroid fluticasone propionate in a form suitable for administration by inhalation, the resulting compositions may be administered on a b.i.d. basis to provide highly effective treatment and/or prophylactic therapy for asthmatics. In particular we believe that such administration has been shown to will lead to significant improvement in daytime lung functions, requirement for additional symptomatic bronchodilator and almost complete abolition of nocturnal asthma while giving rise to minimal systemic side effects.
Salmeterol is one of a range of bronchodilators having extended duration of action which is described in British Patent Specification No. 2140800, and is systematically named 4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol. Fluticasone propionate is one of a range of topical anti-inflammatory corticosteroids with minimal liability to undesired systemic side effects which is described in British Patent Specification No. 2088877, and is systematically named S-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16β-methyl-17α-pripionyloxy-3-oxoandros-1,4-diene-17β-carbothionate. We have found We believe these two compounds to be particularly compatible and complementary in their activity and thus highly effective in the treatment of asthma and other respiratory disorders.
Thus according to one aspect of the invention there are provided pharmaceutical compositions comprising effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.
The invention additionally relates to the use of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionate in the manufacture of pharmaceutical composition as combined preparations for simultaneous, sequential or separate administration of salmeterol and fluticasone propionate by inhalation in the treatment of respiratory element.
According to further feature of the invention there is provided a method of treating respiratory disorders which comprises the simultaneous, sequential or separate administration by inhalation of effective amounts of salmeterol (and/or a physiologically acceptable salt thereof) and fluticasone propionte.
Suitable physiologically acceptable salts of salmeterol include acid addition salts derived from inorganic and organic acids, such as the hydrochloride, hydrobromide, sulphate, phosphonate, maleaste, tartrate, citrate, benzone, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate acetate, fumarate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalencarboxylate e.g. 1-hydroxy- or 3-hydroxy-2-naphthalenecarboxylate, or oleate. Salmeterol is preferably used in the form of its 1-hydroxy-2-napthalene carboxylate salt ( hydroxynaphthoate).
For administration by inhalation, the compositions according to the invention are conveniently delivered by conventional means, e.g. in the form of a metered dose inhaler prepared in a conventional manner or in combinations with a spacer device such as the Volumatic (Glaxo Group trade mark) device. In the case of a metered dose inhaler, a metering valve is provided to deliver a metered amount of the composition. Spray compositions may for example be formulated as aqueous solutions or suspensions and may be administered by a nebuliser. Aerosol spray formations, for example in which the active ingredients are suspended, optionally together with one or more stabilisers, in a propellant, e.g. a halogenated hydrocarbon such as trichlorofluoromethane, dichlorofluoromethane, 1,2-dichlorotetrafluoroethane, trichlorotrifluoroethane, monochloropentafluoroethane, chloroform or methylene chloride, may also be employed. The two drugs may be administered separately in similar ways.
Alternatively, for administration by inhalation or insufflation, the compositions according to the invention may take the form of a dry powder composition, for example a powder mix of the active ingredients and a suitable carrier such as lactose. The powder compositions may be presented in unit dosages form in, for example, capsules, cartridges or blister packs from which the powder may be administered with the aid of an inhaler such as the Rotahaler inhaler (Glaxo Group trade mark) or in the case of blister packs by means of the Diskhaler inhaler (Glaxo Group trade mark).
The ratio of salmeterol to fluctuations propionate in the compositions according to the invention is preferably within the range of 4:1 to 1:20. The two drugs may be administered separately in the same ratio. Each metered dose or actuation of the inhaler will generally contain from 25 μg to 100 μg of salmeterol and from 25 μg to 500 μg of fluticasone propionate. As hereinafter indicated, it is intended that the pharmaceutical compositions will be administered twice daily.
A suitable daily dose of salmeterol for inhalation is in the range 50 μg to 200 μg.
A suitable daily dose of fluticasone propionate for inhalation is in the range 50 μg to 2000 μg depending on the severity of the disease.
The precise dose employed will of course depend on the method of administration, the age, weight and condition of the patient and will be determined by the clinician depending on the severity and the type of asthma.
In order that the invention may be more fully understood, the following example are given by way of illustration only.
EXAMPLE 1 Metered Dose Inhaler
Target per Per Inhaler
Active Ingredient Actuation % w/w
Salmeterol 25.0 μg 0.0448
(as hydroxynaphthoate)
Fluticasone propionate 25.0 μg 0.0309
Stabiliser 5.0 μg 0.0076
Trichlorofluoromethane 23.70 mg 27.8759
Dichlorodifluoromethane 61.25 mg 72.0588
EXAMPLE 2 Metered Dose Inhaler
Target per Per Inhaler
Active Ingredient Actuation % w/w
Salmeterol 25.0 μg 0.0448
(as hydroxynaphthoate)
Fluticasone propionate 50.0 μg 0.0618
Stabiliser 7.5 μg 0.0106
Trichlorofluoromethane 23.67 mg 27.8240
Dichlorodifluoromethane 61.25 mg 72.0588
EXAMPLE 3 Metered Dose Inhaler
Target per Per Inhaler
Active Ingredient Actuation % w/w
Salmeterol 25.0 μg 0.0448
(as hydroxynaphthoate)
Fluticasone propionate 250.0 μg 0.3088
Stabiliser 25.0 μg 0.0309
Trichlorofluoromethane 23.45 mg 27.5567
Dichlorodifluoromethane 61.25 mg 72.0588
EXAMPLE 4 Metered Dose Inhaler
Target per Per Inhaler
Active Ingredient Actuation % w/w
Salmeterol 25.0 μg 0.0448
(as hydroxynaphthoate)
Fluticasone propionate 125.0 μg 0.1544
Stabiliser 15.0 μg 0.0175
Trichlorofluoromethane 23.56 mg 27.7244
Dichlorodifluoromethane 61.25 mg 72.0588
EXAMPLE 5 Metered Dose Inhaler
Target per Per Inhaler
Active Ingredient Actuation % w/w
Salmeterol 100.0 μg 0.1791
(as hydroxynaphthoate)
Fluticasone propionate 250.0 μg 0.3088
Stabiliser 25.0 μg 0.0309
Trichlorofluoromethane 23.43 mg 27.4224
Dichlorodifluoromethane 61.25 mg 72.0588
In Examples 1 to 5 micronised fluticasone propionate and micronised salmeterol (as the hydroxynaphthoate) are added in the proportions given above either dry or after predispersal in a small quantity of stabiliser (disodium dioctylsulphosuccinate, lecithin, oleic acid or sorbitan trioleate)/trichlorofluoromethane solution to a suspension vessel containing the main bulk of the trichlorofluoromethane solution. The resulting suspension is further dispersed by an appropriate mixing system using, for example, a high shear bladder, ultrasonic or a microfluidiser until an ultrafine dispersion is created. The suspension is then continuously recirculated to suitable filling equipment designed for cold fill or pressure filling of dichlorodifluoromethane. Alternatively, the suspension may be prepared in a suitable chilled solution of stabiliser, in trichlorofluoromethane/ dichlorodifluoromethane.
EXAMPLE 6 Metered Dose Dry Powder Formulation
Active Ingredient μg/cartridge or blister
Salmeterol 36.3
(as hydroxynaphthoate)
Fluticasone propionate 50.00
Lactose Ph. Eur. to 12.5 mg or
to 25.0 mg
EXAMPLE 7 Metered Dose Dry Powder Formulation
Active Ingredient μg/cartridge or blister
Salmeterol 72.5
(as hydroxynaphthoate)
Fluticasone propionate 50.00
Lactose Ph. Eur. to 12.5 mg or
to 25.0 mg
EXAMPLE 8 Metered Dose Dry Powder Formulation
Active Ingredient μg/cartridge or blister
Salmeterol 72.5
(as hydroxynaphthoate)
Fluticasone propionate 100.00
Lactose Ph. Eur. to 12.5 mg or
to 25.0 mg
EXAMPLE 9 Metered Dose Dry Powder Formulation
Active Ingredient μg/cartridge or blister
Salmeterol 72.5
(as hydroxynaphthoate)
Fluticasone propionate 250
Lactose Ph. Eur. to 12.5 mg or
to 25.0 mg
EXAMPLE 10 Metered Dose Dry Powder Formulation
Active Ingredient μg/cartridge or blister
Salmeterol 72.5
(as hydroxynaphthoate)
Fluticasone propionate 500.0
Lactose Ph. Eur. to 12.5 mg or
to 25.0 mg
EXAMPLE 11 Metered Dose Dry Powder Formulation
Active Ingredient μg/cartridge or blister
Salmeterol 145.0
(as hydroxynaphthoate)
Fluticasone propionate 250.0
Lactose Ph. Eur. to 12.5 mg or
to 25.0 mg
In Examples 6 to 11 the active ingredients are micronised and bulk blended with the lactose in the proportions given above. The blend is filled into hard gelatin capsules or cartridges or in specifically constructed double foil blister packets (Rotadisks blister packs, Glaxo Group trade mark) to be administered by an inhaler such as the Rotahaler inhaler (Glaxo Group trade mark) or in the case of the blister packs with the Diskhaler inhaler (Glaxo Group trade mark).

Claims (11)

1. A pharmaceutical composition comprising effective amounts of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.
2. A composition as claimed in claim 1, wherein salmeterol is present as its 1-hydroxy-2-naphthalenecarboxylate salt.
3. A composition as claimed in claim 1 presented in the form of a metered dose inhaler or a metered dry powder composition.
4. A composition as claimed in claim 1 in dosage unit form containing 25-100 μg of salmeterol or a physiologically acceptable salt thereof and 25-500 μg of fluticasone propionate per dosage unit.
5. A composition as claimed in claim 2 presented in the form of a metered dose inhaler or a metered dry powder composition.
6. A composition as claimed in claim 2 in dosage unit form comprising 25-100 μg of the 1-hydroxy-2-naphthalenecarboxylate salt of salmeterol and 25-500 μg of fluticasone propionate per dosage unit.
7. A composition as claimed in claim 6 presented in the form of a metered dose inhaler or a metered dry powder composition.
8. The use of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate in the manufacture of pharmaceutical compositions as combined preparations for simultaneous, sequential or separate administration of salmeterol and fluticasone propionate by inhalation in the treatment of respiratory disorders.
9. A method of treating respiratory disorders which comprises the simultaneous, sequential or separate administration by inhalation of effective amounts of salmeterol or a physiologically acceptable salt thereof and fluticasone propionate.
10. A method as claimed in claim 9 wherein the salmeterol or a physiologically acceptable salt thereof and the fluticasone propionate are administered on a twice daily basis.
11. A method as claimed in claim 10 wherein the effective amount of salmeterol or a physiologically acceptable salt thereof 50-200 μg per day and the effective amount of fluticasone propionate is 50-1000 μg per day.
US10/933,483 1989-09-08 2004-09-03 Medicaments Expired - Lifetime USRE40045E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/933,483 USRE40045E1 (en) 1989-09-08 2004-09-03 Medicaments

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
US57860190A 1990-09-07 1990-09-07
US07/753,907 US5270305A (en) 1989-09-08 1991-09-03 Medicaments
US10/933,483 USRE40045E1 (en) 1989-09-08 2004-09-03 Medicaments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/753,907 Reissue US5270305A (en) 1989-09-08 1991-09-03 Medicaments

Publications (1)

Publication Number Publication Date
USRE40045E1 true USRE40045E1 (en) 2008-02-05

Family

ID=27450403

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/753,907 Ceased US5270305A (en) 1989-09-08 1991-09-03 Medicaments
US10/933,483 Expired - Lifetime USRE40045E1 (en) 1989-09-08 2004-09-03 Medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07/753,907 Ceased US5270305A (en) 1989-09-08 1991-09-03 Medicaments

Country Status (1)

Country Link
US (2) US5270305A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042171A1 (en) * 2001-10-12 2005-02-24 Gavin Brian Charles Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US20060222667A1 (en) * 2003-05-13 2006-10-05 The Foundry, Inc. Apparatus for treating asthma using neurotoxin
US20070253913A1 (en) * 2003-09-10 2007-11-01 Nahed Mohsen Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US20090306644A1 (en) * 2008-05-09 2009-12-10 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US20100081664A1 (en) * 2007-02-11 2010-04-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20110152855A1 (en) * 2009-10-27 2011-06-23 Mayse Martin L Delivery devices with coolable energy emitting assemblies
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
WO2012041031A1 (en) 2010-09-28 2012-04-05 健乔信元医药生技股份有限公司 Compound composition for inhalation used for treating asthma
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
DK0617610T3 (en) * 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspension aerosol.
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
EE03997B1 (en) * 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Albuterol metered dose inhaler
EE9700372A (en) 1995-04-14 1998-06-15 Glaxo Wellcome Inc. Beclomethasone dipropionate metered dose inhaler
RO119117B1 (en) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Fixed dose inhaler for fluticasone propionate
EP1547636A1 (en) 1995-04-14 2005-06-29 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US6135628A (en) * 1995-10-13 2000-10-24 Boehringer Ingelheim Pharmceuticals, Inc. Method and apparatus for homogenizing aerosol formulations
IL136951A0 (en) * 1998-01-16 2001-06-14 Takeda Chemical Industries Ltd Sustained-release composition, method of its production and use thereof
US5993782A (en) * 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
US20030209453A1 (en) * 2001-06-22 2003-11-13 Herman Craig Steven Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6479035B1 (en) * 1999-09-11 2002-11-12 Smithkline Beecham Corporation Pharmaceutical formulation of fluticasone propionate
US20040089561A1 (en) * 1999-11-23 2004-05-13 Herman Craig Steven Method and package for storing a pressurized container containing a drug
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
KR20060011783A (en) * 2002-06-12 2006-02-03 에피제네시스 파마슈티칼스 아이엔씨 Composition, formulations and kit for treatment of respiratory and lung disease with dehydroepi androsterone(s) steroid and an anti-muscarinic agent(s)
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
WO2003105775A2 (en) * 2002-06-17 2003-12-24 Epigenesis Pharmaceuticals, Inc. Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
AU2003293361A1 (en) * 2002-12-18 2004-07-29 Glaxo Group Limited Drug delivery system with vented mouthpiece
SE527200C2 (en) * 2003-06-19 2006-01-17 Microdrug Ag Administration of metered dry powder combined doses of finely divided dry medication powders involves selecting first and second medicaments for forming of pharmaceutical, combined doses
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
SE0303270L (en) * 2003-12-03 2005-06-04 Microdrug Ag Method of administration of tiotropium
SE0303570L (en) * 2003-12-03 2005-06-04 Microdrug Ag Moisture-sensitive medical product
WO2005053647A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Medical product containing tiotropium
SE530006C2 (en) * 2004-06-18 2008-02-05 Mederio Ag Inhaler using tub
GB0415789D0 (en) * 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
ES2385934T3 (en) 2004-08-20 2012-08-03 Mannkind Corporation CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA.
KR101644250B1 (en) 2004-08-23 2016-07-29 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
WO2007011743A2 (en) 2005-07-14 2007-01-25 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7981981B2 (en) * 2006-03-09 2011-07-19 Ticona Llc Flexible, hydrocarbon-resistant polyarylenesulfide compounds and articles
PL2077830T3 (en) * 2006-10-17 2013-04-30 Lithera Inc Methods, compositions, and formulations for the treatment of thyroid eye disease
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5667095B2 (en) 2009-03-11 2015-02-12 マンカインド コーポレイション Apparatus, system and method for measuring inhaler resistance
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CA2764505C (en) 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
JP2013517294A (en) * 2010-01-15 2013-05-16 リセラ，インク． Freeze-dried cake formulation
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
US8834411B2 (en) 2011-04-06 2014-09-16 Mystic Pharmaceuticals, Inc. Medical devices for dispensing powders
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US9493646B2 (en) 2012-04-13 2016-11-15 Ticona Llc Blow molded thermoplastic composition
US9758674B2 (en) 2012-04-13 2017-09-12 Ticona Llc Polyarylene sulfide for oil and gas flowlines
US9494260B2 (en) 2012-04-13 2016-11-15 Ticona Llc Dynamically vulcanized polyarylene sulfide composition
US9494262B2 (en) 2012-04-13 2016-11-15 Ticona Llc Automotive fuel lines including a polyarylene sulfide
US9765219B2 (en) 2012-04-13 2017-09-19 Ticona Llc Polyarylene sulfide components for heavy duty trucks
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
ES2754388T3 (en) 2013-03-15 2020-04-17 Mannkind Corp Compositions and methods of microcrystalline dicetopiperazine
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US9718225B2 (en) 2013-08-27 2017-08-01 Ticona Llc Heat resistant toughened thermoplastic composition for injection molding
US9757892B2 (en) 2013-08-27 2017-09-12 Ticona Llc Thermoplastic composition with low hydrocarbon uptake
WO2015091285A1 (en) * 2013-12-19 2015-06-25 Almirall S.A. Dosage formulation comprising salmeterol and fluticasone propionate
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA41378A (en) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc DRY POWDER INHALER CONSISTING OF FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
US20220296825A1 (en) * 2018-10-04 2022-09-22 Optinose As Exhalation delivery system for and method of treating sinus disease

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199578A (en) 1977-11-30 1980-04-22 Fisons Limited Composition
US4278673A (en) * 1977-03-25 1981-07-14 Allen & Hanburys Limited Pharmacologically active compounds
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
GB2088877A (en) 1980-02-15 1982-06-16 Glaxo Group Ltd Androstane 17 beta carbothioates
US4352789A (en) 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
GB2107715A (en) 1981-10-19 1983-05-05 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB2140800A (en) 1983-04-18 1984-12-05 Glaxo Group Ltd Phenethanolamine derivatives
US4513001A (en) * 1982-03-24 1985-04-23 Laboratoire Roger Bellon β-Adrenergic 1-[1-benzimidazolyl]-N-[2-(4-hydroxy-3-methoxy-phenyl)-2-hydroxy-ethyl]-3-amino butane and salts and hydrates thereof
US4578221A (en) 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
EP0223671A1 (en) 1985-10-16 1987-05-27 Centre International De Recherches Dermatologiques Galderma - Cird Galderma Medicament with a synergistic anti-inflammatory effect on the basis of a corticosteroid and a beta-agonist
WO1987005213A1 (en) 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation
GB2187953A (en) 1986-03-15 1987-09-23 Fisons Plc Nedocromil composition
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4811731A (en) * 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
US4814161A (en) * 1985-01-16 1989-03-21 Riker Laboratories, Inc. Drug-containing chlorofluorocarbon aerosol propellent formulations
US4866051A (en) * 1981-10-19 1989-09-12 Glaxo Group Limited Micronised beclomethasone dipropionate monohydrate compositions and methods of use
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
WO1990006775A1 (en) 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
US4985418A (en) * 1986-12-24 1991-01-15 Glaxo Group Limited Pharmaceutical compositions
EP0416951A1 (en) 1989-09-08 1991-03-13 Glaxo Group Limited Medicaments comprising salmeterol and fluticason
GB2235626A (en) 1989-09-08 1991-03-13 Glaxo Group Ltd Medicaments for treating respiratory disorders
GB2235627A (en) 1989-09-08 1991-03-13 Glaxo Group Ltd Inhalation medicaments
US5208226A (en) 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5955439A (en) * 1994-12-24 1999-09-21 Glaxo Group Limited Pharmaceutical aerosol containing at least one sugar
US6143277A (en) * 1995-04-14 2000-11-07 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
US6153173A (en) * 1994-12-10 2000-11-28 Glaxo Group Limited Propellant mixture for aerosol formulation
US6253762B1 (en) * 1995-04-14 2001-07-03 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US6880722B2 (en) * 2000-10-31 2005-04-19 Glaxo Group Limited Medicament dispenser
US6926178B1 (en) * 1999-08-07 2005-08-09 Glaxo Group Limited Valve with a two-component seal

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278673A (en) * 1977-03-25 1981-07-14 Allen & Hanburys Limited Pharmacologically active compounds
US4199578A (en) 1977-11-30 1980-04-22 Fisons Limited Composition
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
GB2088877A (en) 1980-02-15 1982-06-16 Glaxo Group Ltd Androstane 17 beta carbothioates
US4352789A (en) 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4578221A (en) 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
GB2107715A (en) 1981-10-19 1983-05-05 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
US4866051A (en) * 1981-10-19 1989-09-12 Glaxo Group Limited Micronised beclomethasone dipropionate monohydrate compositions and methods of use
US4513001A (en) * 1982-03-24 1985-04-23 Laboratoire Roger Bellon β-Adrenergic 1-[1-benzimidazolyl]-N-[2-(4-hydroxy-3-methoxy-phenyl)-2-hydroxy-ethyl]-3-amino butane and salts and hydrates thereof
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2140800A (en) 1983-04-18 1984-12-05 Glaxo Group Ltd Phenethanolamine derivatives
US5091422A (en) 1983-04-18 1992-02-25 Glaxo Group Limited Phenethanolamine derivatives
US4814161A (en) * 1985-01-16 1989-03-21 Riker Laboratories, Inc. Drug-containing chlorofluorocarbon aerosol propellent formulations
US4811731A (en) * 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
EP0223671A1 (en) 1985-10-16 1987-05-27 Centre International De Recherches Dermatologiques Galderma - Cird Galderma Medicament with a synergistic anti-inflammatory effect on the basis of a corticosteroid and a beta-agonist
WO1987005213A1 (en) 1986-03-04 1987-09-11 Chiesi Farmaceutici S.P.A. New pharmaceutical compositions for inhalation
GB2187953A (en) 1986-03-15 1987-09-23 Fisons Plc Nedocromil composition
US4985418A (en) * 1986-12-24 1991-01-15 Glaxo Group Limited Pharmaceutical compositions
WO1990006775A1 (en) 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
EP0416951A1 (en) 1989-09-08 1991-03-13 Glaxo Group Limited Medicaments comprising salmeterol and fluticason
GB2235626A (en) 1989-09-08 1991-03-13 Glaxo Group Ltd Medicaments for treating respiratory disorders
GB2235627A (en) 1989-09-08 1991-03-13 Glaxo Group Ltd Inhalation medicaments
US5208226A (en) 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US6919069B2 (en) * 1991-12-12 2005-07-19 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US6251368B1 (en) * 1991-12-12 2001-06-26 Glaxo Group Limited Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US6153173A (en) * 1994-12-10 2000-11-28 Glaxo Group Limited Propellant mixture for aerosol formulation
US5955439A (en) * 1994-12-24 1999-09-21 Glaxo Group Limited Pharmaceutical aerosol containing at least one sugar
US6253762B1 (en) * 1995-04-14 2001-07-03 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US6143277A (en) * 1995-04-14 2000-11-07 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
US6926178B1 (en) * 1999-08-07 2005-08-09 Glaxo Group Limited Valve with a two-component seal
US6880722B2 (en) * 2000-10-31 2005-04-19 Glaxo Group Limited Medicament dispenser

Non-Patent Citations (102)

* Cited by examiner, † Cited by third party
Title
ABPI data sheet compendium entry for 1988-9 ("the VENTIDE data sheet").
Allergy and asthma, new trends and approaches to therapy. (Proceedings of a November 1987 conference) Ed. by A.B. Kay, Blackwell Scientific Publications, Boston, MA (1989).
Anani, A. et al., Breath-actuated inhalers: comparison of terbutaline Turbohaler with salbutamol Rotahaler, European Respiratory Journal, 2:640-642 (1989).
Arossa, W. et al., Salbutamol plus beclomethasone dipropionate versus theophylline for the prevention of methacholine-induced bronchospasm in patients with chronic bronchitis, International Journal of Clinical Pharmacology, Therapy and Toxicology, 23(10):565-568 (1985).
Ball, D.I. et al., Bronchodilator Activity of Salmeterol, A Long-acting beta<SUB>2</SUB>-Adrenoceptor Agonist, British Journal of Pharmacology, 92:746P (1987).
Ball, D.I. et al., In Vitro Characterisation of the beta<SUB>2</SUB>-Adrenoceptor agonist, Salmeterol, British Journal of Pharmacology, vol. 92:591P (1987).
Barazzone, C., Asthme: nouveautés thérapeutiques (Asthma: new therapies), Médecine et Hygiene, 48:3642-3645 (1990).
Barnes, P.J., The Drug Therapy of Asthma: Directions for the 21st Century, Directions for New Anti-Asthma Drugs, 293-313 (Stella R. O'Donnell et al. eds. 1988).
Bateman, E.D. et al., Salmeterol/Fluticasone Combination Inhaler, A New, Effective and Well Tolerated Treatment for Asthma, Clin. Drug. Invest., 16(3):193-201 (1998).
Bauer, K. et al., The Effect of Inhaled Fluticasone Propionate (FP), A New Potent Corticosteriod in Severe Asthma, European Respiratory Journal, 1 (Suppl. 2): 201S (1988) (Abstract).
Bennati, D. et al., Changes in Bronchial Reactivity in Asthmatic Children After Treatment with Beclomethasone Alone or in Association with Salbutamol, Journal of Asthma, 26(6):359-364 (1989).
Bloomfield, P. et al., Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma, British Medical Journal, 1(6167):848-850 (1979).
Bradshaw, J. et al., The Design of Salmeterol, a Long-acting Selective beta<SUB>2</SUB>-adrenoceptor agonist, Brit. Pharm. Soc'y, Oxford, England, UK, Sep. 9-11, 1987. Br. J. Pharmacology 92 Suppl. (1987) (Abstract 590P).
British Thoracic Society, Guidelines for management of asthma in adults: I-Chronic persistent asthma, British Medical Journal, 301: 651-653 (Sep. 29, 1990).
Brittain et al, Further Studies on the long duration of action of salmeterol, a new, selective Beta<SUB>2</SUB>-stimulant bronchodilator, 125th Brit. Pharm. Conference, Aberdeen, Scotland, UK, Sep. 11-17, 1988, J. Pharm. Pharmacology 40 Suppl. (1988) (Abstract 93P).
Bronchodilators, in New Yakurigaku ("New Pharmacology"), Ed. by Chikako Tanaka and Ryuichi Katoh, Nankoudou, K.K., 427-428 (1989).
Butchers, P.R. et al., Salmeterol: A potent and long-acting inhibitor of the release of inflammatory and spasmogenic mediators from human lung, British Journal of Pharmacology, 92:745P (1987).
Cameron, S.J. et al., Substitution of Beclomethasone Aerosol for Oral Prednisolone in the Treatment of Chronic Asthma, British Medical Journal, 4(5886):205-207 (1973).
Carmichael, J. et al., Beclomethasone dipropionate dry-powder inhalation compared with conventional aerosol in chronic asthma, British Medical Journal, 2(6137):657-658 (1978).
Carmichael, J. et al., Corticosteroid resistance in chronic asthma, British Medical Journal, 282(6274):1419-1422 (1981).
Chapman, K.R. et al., Salmeterol and fluticasone propionate (50/250 mug) administered via combination Diskus inhaler: As effective as when given via separate Diskus Inhalers, Can. Resp. J., 6(1):45-51 (1999).
Chung, K.F. et al., Drug Treatment of Asthma, Drugs of Today, 25(11):721-732 (1989).
Church, M.K. et al., Influence of Salbutamol and Sodium Cromoglycate on Mast Cell Mediator Release In Vivo, The Journal of Allergy and Clinical Immunology, 75(1-Part 2):195 (1985) (Abstract 361).
Clark, R.A. et al., Is 200 mug Beclomethasone Diproprionate (BDP) Twice Daily as Effective as 100 mug Given Four Times Each Day?, Scottish Medical Journal, 30:195 (1985).
Clark, T.J.H. et al., The effects of beclomethasone dipropionate aerosol given in high doses to patients with asthma, Postgraduate Medical Journal, 51(Suppl. 4):72-75 (1975).
Clarke, S.W. et al., Therapeutic aerosols 2-Drugs available by the inhaled route, Thorax, 39(1):1-7 (1984).
Cochrane, G.M. et al., A Colour Atlas of Asthma (1989).
Cochrane, G.M., et al., Algorithms for treatment of asthma, A Colour Atlas of Asthma, 125-129 (1989).
Cochrane, G.M., Inhaled Steroids and their role in the treatment of asthma, Bronchus, 2(3):8 (1987).
Cochrane, G.M., The Difficult Chronic Asthmatic, Br. J. Dis. Chest, 81(4): 313-320 (1987).
Combined inhaler is key to therapy, General Practitioner (Feb. 2, 1990).
Cooke, N.J. et al., Response to Rimiterol and Salbutamol Aerosols Administered by Intermittent Positive-pressure Ventilation, British Medical Journal, 2(5913):250-252 (1974).
Costello, J.F. et al., Nebulised salbutamol in life-threatening asthma, and further letters of Anderson, P.B. and Bloomfield, P. et al., British Medical Journal, 1(6173):1284-1285 (1979).
Costello, J.F. et al., Response of patients receiving high dose beclomethasone dipropionate, Thorax, 7(29):571-573 (1974).
Crane, J. et al., Prescribed Fenoterol and Death from Asthma in New Zealand, 1981-83: Case-Control Study, The Lancet, 917-922 (1989).
Creemers, J.P.H.M. et al., A Multicentre Comparative Study of Salbutamol Controlled Release (Volmax)(R) and Sustained-Release Theophylline (Theo-dur)(R) in the Control of Nocturnal Asthma, The European Respiratory Journal Abstracts Book, 1(Supplement 2):333s (1988).
Crompton, G., Intravenous beta-agonist in severe acute asthma, British Medical Journal, and further letters of Ward, M.J. and McKay, S. et al., 297(6651):791-792 (1988).
Crompton, G.K., "All asthmatics should have inhaler therapy," The Pharmaceutical Journal, 232(6270):365-366 (1984).
Crompton, G.K., High dose inhaled steroids, Research and Clinical Forums, 11:51 (1989).
Crompton, G.K., Illogical warnings on Ventolin inhalers, Br. Med. J (Clin Res. Ed), 288(6425):1231 (1984).
Dal Negro, R.W. et al., Airways Flow Limitation: Acute Responsiveness to Combined Salbutamol+Beclomethasone Dipropionate (Ventolin(R) Flogo), Current Therapeutic Research, 35(4):561-565 (1984).
Dal Negro, R.W. et al., Chronic Airways Obstruction Responsiveness to Combined, Pressurized Salbutamol-Beclomethasone Dipropionate (Ventolin Flogo*), Clinical Trials Journal, 20(6):366-372 (1983).
Davies, Saffron, Health: Breathing space is not the same as a cure for asthmatics: Saffron Davies on the fears that new drugs to cope with the symptoms of asthma neglect to treat the disease itself, The Independent (Apr. 18, 1989).
Deucher, N., Salmeterol-new 'designer' bronchodilator, Pulse, 14:86 (1989).
Douglas, J.G. et al., A Comparative Study of Two Doses of Salbutamol Nebulized at 4 and 8 Litres per Minute in Patients with Chronic Asthma, British Journal of Diseases of the Chest, 80(1):55-58 (1986).
Douglas, J.G. et al., Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe?, Thorax, 40(3):180-183 (1985).
Drazen, J.M. et al., Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma, The New England Journal of Medicine, 335(12):841-847 (1996).
Duncan, D. et al., Comparison of the Bronchodilator Effects of Salbutamol Inhaled as a Dry Powder and by Conventional Pressurised Aerosol, British Journal of Clinical Pharmacology, 4(6):669-671 (1977).
Duncan, D. et al., Salbutamol in the treatment of asthma, The Practitioner, 223:843-844 (1979).
Entzian, P. et al., Glucocorticoid receptor binding is influenced by a beta adrenoceptor agonist in vitro, Department of Medicine, Christian-Albrechts-Universitat, Kiel, FRG European Respiratory Journal, 1 (Suppl. 2): 196S (1988) (Abstract).
Expert calls for dual drugs in asthma, General Practitioner, 19 (Mar. 17, 1989).
Extract from British National Formulary No. 16, "Drugs used in the treatment of diseases of the respiratory system," Chapter 3, 113-123 (1988).
Extracts from MIMS (1989) and MIMS (1990).
Fancourt, G.J. et al., The effects of high does (2000 micrograms/day) inhaled Beclomethasone dipropionate (Becloforte) on glucose tolerance in diet controlled elderly diabetic subjects, Leicester General Hospital Leicester, England European Respiratory Journal, 1 (Suppl. 2): 196S (1988) (Abstract).
Ferguson, A.C., Persistence of Bronchial Hyper-Responsiveness in Asthmatic Children Treated with Inhaled Beclomethasone, Supplement to Clinical and Investigative Medicine, 12(4):B5 (1989) (Abstract R-4).
Fergusson, R.J. et al., Nebulized Salbutamol in Life-Threatening Asthma: Is IPPB Necessary?, British Journal of Diseases of the Chest, 77(3):255-261 (1983).
Fischbacher, C.M. et al., Comparison of Duovent and Salbutamol Inhalers in Chronic Stable Asthma, Scottish Medical Journal, 30:195 (1985).
Flatt, A. et al., Comparison of Cardiovascular Effects of Inhaled Fenoterol, Salbutamol and Placebo, The European Respiratory Journal Abstracts Book, 1(Supplement 2):333s (1988).
Gader, A.M.A. et al., Fibrinoltic, Factor VIII and Pulse Rate Responses to Intravenous Adreline During Chronic Oral Salbutamol Administration, Thrombosis Research, 3(2):137-143 (1973).
Galleguillos, F., Study on the Association of Beclomethasone Dipropionate (BDP) and Salbutamol Ventide(R) In the Treatment of Asthma, Annals of Allergy (55 2 of Pt. 2) 407:Abstract 726 (1985).
Glaxo's R&D progressing on target, SCRIP No. 1411 (May 12, 1989).
Grant, I.W.B. et al., Becloforte inhaler, and further letter from Slessor, I.M. in British Medical Journal, 286(6365):645 (1983).
Grant, I.W.B. et al., Beclomethasone Aerosol in Chronic Bronchial Asthma, with further letter of Turner-Warwick, M. et al., The Lancet, II(7884):838-839 (1974).
Gregg, I., A new treatment for asthma: promotional expediency versus pharmaceutical responsibility, with further letter of Slessor, I.M., British Medical Journal, 288(6410):68-69 (1984).
Gregg, I., Treatment of Asthma with Beclomethasone Aerosol, with further letter of Grant, I.W.B. et al., British Medical Journal, 2(5805):110 (1972).
Haahtela, T. et al., The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma, Annals of Allergy, 62(1):63-66 (1989).
Harding et al, A Comparison of the Tolerance and Systemic Effects of Fluticasone Propionate (FP) and Beclomethasone Dipropionate (BDP) in Healthy Volunteers, European Respiratory Journal, 1 (2): 196S, 1988. *
Harding, S.M. et al., A Comparison of the Tolerance and Systemic Effects of Fluticasone Propionate (FP) and Beclomethasone Dipropionate (BDP) in Healthy Volunteers, European Respiratory Journal, 1 (Suppl. 2): 196S (1988) (Abstract).
Holtkamp, U., Glucocorticoide früher einsetzen (Apply Glucocorticoids Earlier), Deutsche Apotheker Zeitung (German Pharmacists Journal), 130(8):407-408 (1990).
Howarth, P.H. et al., Influence of Salbutamol and Sodium Cromoglycate on Mast Cell Mediator Release in vivo, Respiration, 46(S1):22-23 (1984) (Abstract).
Ind, P.W., Rational treatment of asthma, British Medical Journal, 288(6415):484-485 (1984).
Jack, D., The Challenge of Drug Discovery, Drug Design and Delivery, 4(3):167-186 (J.S. Morley et al. eds., Harwood Academic Publishers 1989).
Jeppsson, A.B. et al., Pharmacodynamic and pharmacokinetic aspects on the transport of bronchodilator drugs through the tracheal epithelium of the guinea pig, Pharmacol. Toxicol. (Copenhagen), 64(1):58-63 (Chemical Abstracts 110:147583r) (1989).
Jeppsson, A.-B. et al., Pharmacodynamic and Pharmacokinetic Aspects on the Transport of Bronchodilator Drugs Through the Tracheal Epithelium of the Guinea-Pig, Pharmacology & Toxicology, 64(1):58-63 (1989).
Joubert, J.R. et al., Inhalation therapy during acute asthma, South African Medical Journal, 68(6):381-384 (1985).
Kemp, J.P. et al., A Comparative Study of Salmeterol, Albuterol, and Placebo via MDI in Asthmatic Adults, The Journal of Allergy and Clinical Immunology, 83(1):186 (1989) (Abstract 58).
Kerrebijn, K.F. et al., Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma, J. Allergy Clin. Immunol., 79(4):653-659 (1987).
Konig, P., The role of inhaled steroids in the treatment of asthma, Respiratory Medicine, 83(Supplement A):43-47 (1989).
Kotaniemi, J. et al., Salbutamol Controlled Release Tablets (Volmax)(R) and Individually Titrated Slow Release Theophylline (Theo-Dur)(R) in the management of Chronic Obstructive Airways Disease (COAD), Central Hospitals, Sweden European Respiratory Journal, 1 (Suppl. 2): 196S (1988) (Abstract).
Kraan, J. et al., Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic ashtma: A comparison between budesonide and terbutaline, J. Allergy Clin. Immunol., 76(4):628-636 (1985).
Leitch, A.G. et al., Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men, British Medical Journal, 1(6006):365-367 (1976).
Lindsay, Fixed does combination therapy in the treatment of asthma-the case against it, Mechanism in Asthma: Pharmacology, Physiology and Management, pp. 421-425 (1988).
Lipworth, B. et al., The Pharmacokinetics of Salbutamol Controlled Release Tablets (SCR) in Asthmatic Patients, The European Respiratory Journal Abstracts Book, 1(Supplement 2):333s (1988).
Lipworth, B.J. et al., Airways, tremor and haemodynamic responses to inhaled salbutamol in normal subjects, British Journal of Clinical Pharmacology, 26(2):208P-209P (1988).
Lipworth, B.J. et al., Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of 2-adrenoceptor blockade, British Journal of Clinical Pharmacology, 28(1):95-102 (1989).
Lipworth, B.J. et al., beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma, British Journal of Clinical Pharmacology, 26(5):527-533 (1988).
Martindale The Extra Pharmacopoeia, 882-883 (James E. F. Reynolds et al. eds., The Pharmaceutical Press, 29th ed. 1989).
McDonald, C. et al., Evaluation of the combination inhaler of salbutamol and beclomethasone dipropionate in the management of asthma, Current Medical Research and Opinion, 11(2):116-122 (1988).
Mikhail et al, Is twice daily prophylaxis with salbutamol and beclomethasone dipropionate effective in the management of asthma, Pharmatherapeutica, vol. 4 (10), 1986. *
Mikhail, J.R. et al., is twice daily prophylaxis with salbutamol and beclomethasone dipropionate effective in the management of asthma?, Pharmatherapeutica, 4(10):648-654 (1986).
Mitchell, E.A., Is current treatment increasing asthma mortality and morbity?, 44 Thorax 81-84 (1989).
Muers, M. et al., Effect of a timed interval between inhalation of beta-agonist and corticosteroid aersols on the control of chronic asthma, Thorax, 38:378-382 (1983).
Nolte, D., Glucocorticoide in der Asthmatherapie, Deutsche Medizinische Wochenschrift, 114:1411-1415 (1989), together with English translation appended thereto "Glucocorticoids in the treatment of asthma".
Page, C.P., Developments in Asthma: A view of current research (PJB Publications Ltd. 1987).
Page, C.P., One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta<SUB>2</SUB>-agonists, The Lancet, 37:717-720 (1991).
Perri, G. et al., Salbutamol plus beclomethasone dipropionate (Ventolin Flogo) vs. fenoterol (Dosberotec) in chronic obstructive lung disease therapeutic strategy: a 4-week clinical trial, International Journal of Clinical Pharmacology, Therapy and Toxicology, 23(5):274-278 (1985).
Sears, M.R. et al., Regular inhaled beta-agonist treatment in bronical asthma, The Lancet, 336:1391-96 (1990).
Twentyman, O.P. et al., Controversies in respiratory medicine: regular inhaled beta-agonists-clear clinical benefit or a hazar to health? (1) beta-agonists can be used safely and beneficially in asthma, Respiratory Medicine, 86:471-476 (1992).
Ullman et al, Salmeterol, a new long acting inhaled beta-2-adrenoceptor agonist: comparison with sulbutamol in adult asthmatic patients, Thorax, 1988, 43:674-678. *
Vathenen, A.S. et al., Rebound Increase in Bronchial Responsiveness after Treatment with Inhaled Terbutaline, The Lancet, 554-557 (1988).
Ventolin compositum, Unlisted Drugs 33(6):101c (1981).
Woolcock, A.J., Aerosol Bronchodilators in Preventive Treatment of Asthma, Drugs 15:1-2 (1978).

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042171A1 (en) * 2001-10-12 2005-02-24 Gavin Brian Charles Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma
US10953170B2 (en) 2003-05-13 2021-03-23 Nuvaira, Inc. Apparatus for treating asthma using neurotoxin
US20060222667A1 (en) * 2003-05-13 2006-10-05 The Foundry, Inc. Apparatus for treating asthma using neurotoxin
US8172827B2 (en) 2003-05-13 2012-05-08 Innovative Pulmonary Solutions, Inc. Apparatus for treating asthma using neurotoxin
US9339618B2 (en) 2003-05-13 2016-05-17 Holaira, Inc. Method and apparatus for controlling narrowing of at least one airway
US20070253913A1 (en) * 2003-09-10 2007-11-01 Nahed Mohsen Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20100284940A1 (en) * 2007-02-11 2010-11-11 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20100081663A1 (en) * 2007-02-11 2010-04-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US7994197B2 (en) 2007-02-11 2011-08-09 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8119639B2 (en) 2007-02-11 2012-02-21 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20100081664A1 (en) * 2007-02-11 2010-04-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US11058879B2 (en) 2008-02-15 2021-07-13 Nuvaira, Inc. System and method for bronchial dilation
US9125643B2 (en) 2008-02-15 2015-09-08 Holaira, Inc. System and method for bronchial dilation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US8489192B1 (en) 2008-02-15 2013-07-16 Holaira, Inc. System and method for bronchial dilation
US8731672B2 (en) 2008-02-15 2014-05-20 Holaira, Inc. System and method for bronchial dilation
US8821489B2 (en) 2008-05-09 2014-09-02 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US9668809B2 (en) 2008-05-09 2017-06-06 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8808280B2 (en) 2008-05-09 2014-08-19 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US11937868B2 (en) 2008-05-09 2024-03-26 Nuvaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US20090306644A1 (en) * 2008-05-09 2009-12-10 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961507B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961508B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US10149714B2 (en) 2008-05-09 2018-12-11 Nuvaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8088127B2 (en) 2008-05-09 2012-01-03 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8226638B2 (en) 2008-05-09 2012-07-24 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
US9931162B2 (en) 2009-10-27 2018-04-03 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
US9005195B2 (en) 2009-10-27 2015-04-14 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8740895B2 (en) 2009-10-27 2014-06-03 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9649153B2 (en) 2009-10-27 2017-05-16 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US20110152855A1 (en) * 2009-10-27 2011-06-23 Mayse Martin L Delivery devices with coolable energy emitting assemblies
US8932289B2 (en) 2009-10-27 2015-01-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9675412B2 (en) 2009-10-27 2017-06-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9017324B2 (en) 2009-10-27 2015-04-28 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8777943B2 (en) 2009-10-27 2014-07-15 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US10610283B2 (en) 2009-11-11 2020-04-07 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9649154B2 (en) 2009-11-11 2017-05-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US11389233B2 (en) 2009-11-11 2022-07-19 Nuvaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US11712283B2 (en) 2009-11-11 2023-08-01 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
WO2012041031A1 (en) 2010-09-28 2012-04-05 健乔信元医药生技股份有限公司 Compound composition for inhalation used for treating asthma
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation

Also Published As

Publication number Publication date
US5270305A (en) 1993-12-14

Similar Documents

Publication Publication Date Title
USRE40045E1 (en) Medicaments
CA2024916C (en) Respiratory disorder medicaments comprising salmeterol and fluticasone propionate
US5208226A (en) Medicaments
CA2024872C (en) Medicaments
RU2162689C2 (en) Proliposomal powder for inhalation
US5674860A (en) Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
SK283338B6 (en) Use of mometasone furoate for treating airway passage and lung diseases
US6369115B1 (en) Stabilized powder formulations
GB2235627A (en) Inhalation medicaments
US8877740B2 (en) Compound composition for inhalation used for treating asthma
WO2000053187A1 (en) New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
EP0613371B1 (en) New combination of formoterol and budesonide
KR100294834B1 (en) Pharmaceutical composition for the treatment of respiratory diseases
MXPA97004406A (en) Proliposomas powders for inhalac